Skip to main content

Advertisement

SpringerLink
Log in

Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The global physiological function of specifically expressed genes of prostate cancer in Chinese patients is unclear. This study aims to determine the genome-wide expression of genes related to prostate cancer in the Chinese population. Genes that were differentially expressed in prostate cancer were identified using DNA microarray technology. Expressions were validated by using real-time PCR. The identified genes were analyzed using the ingenuity pathway analysis (IPA) to investigate the gene ontology, functional pathway and network. A total of 1,444 genes (Fold time ≥ 1.5; P ≤ 0.05) were differentially expressed in prostate primary tumor tissue compared with benign tissue. IPA revealed a unique landscape where inductions of certain pathways were involved in Cell Cycle Regulation and proliferation. Network analysis not only confirmed that protein interactions lead to the deregulation of DNA Replication, Recombination and Repair, Cellular Compromise and Cell Cycle, Genetic Disorders and Connective Tissue Disorders, but it was also observed that many of the genes regulated by Myc contributed to the modulation of lipid Metabolism and Nucleic Acid Metabolism. Both pathway and network analysis exhibited some remarkable characteristics of prostate cancer for Chinese patients, which showed profound differences from that of other non-Chinese populations. These differences may provide new insights into the molecular cascade of prostate cancer that occurs in Chinese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Mettlin C. Recent developments in the epidemiology of prostate cancer. Eur J Cancer. 1997;33:340–7.

    Article  PubMed  CAS  Google Scholar 

  3. Hughes C, Murphy A, Martin C, Sheils O, O’Leary J. Molecular pathology of prostate cancer. J Clin Pathol. 2005;58:673–84.

    Article  PubMed  CAS  Google Scholar 

  4. Quinn DI, Henshall SM, Sutherland LR. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005;41:858–87.

    Article  PubMed  CAS  Google Scholar 

  5. Endo T, Uzawa K, Suzuki H, Tanzawa H, Ichikawa T. Characteristic gene expression profiles of benign prostatic hypertrophy and prostate cancer. Int J Oncol. 2009;35:499–509.

    PubMed  CAS  Google Scholar 

  6. Savli H, Szendröi A, Romics I, Nagy B. Gene network and canonical pathway analysis in prostate cancer: a microarray study. Exp Mol Med. 2008;40:176–85.

    Article  PubMed  CAS  Google Scholar 

  7. Alavanja MC, Samanic C, Dosemeci M, Lubin J, Tarone R, Lynch CF, Knott C, Thomas K, Hoppin JA, Barker J, Coble J, Sandler DP, Blair A. Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. Am J Epidemiol. 2003;157(9):800–14.

    Article  PubMed  Google Scholar 

  8. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.

    Article  PubMed  CAS  Google Scholar 

  9. Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol. 2008;286:40–8.

    Article  PubMed  CAS  Google Scholar 

  10. Fujinami K, Uemura H, Ishiguro H, Kubota Y. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP. Int J Mol Med. 2002;10:173–6.

    PubMed  CAS  Google Scholar 

  11. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–65.

    Article  PubMed  CAS  Google Scholar 

  12. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6:307–20.

    Article  PubMed  Google Scholar 

  13. Scott A, Wang Z. Tumour suppressor function of protein tyrosine phosphatase receptor-T. Biosci Rep. 2011;31:303–7.

    Article  PubMed  CAS  Google Scholar 

  14. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 2004;304:1164–6.

    Article  PubMed  CAS  Google Scholar 

  15. Wellcome Trust Case Control Consortium. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature. 2007;447:661–78.

    Article  Google Scholar 

  16. Murabito JM, Rosenberg CL, Finger D, Kreger BE, Levy D, Splansky GL, Antman K, Hwang SJ. A genome-wide association study of breast and prostate cancer in the NHLBI’s Framingham Heart Study. BMC Med Genet. 2007;8(Suppl 1):S6.

    Article  PubMed  Google Scholar 

  17. Birkenkamp-Demtroder K, Mansilla F, Sørensen FB, Kruhøffer M, Cabezón T, Christensen LL, Aaltonen LA, Verspaget HW, Ørntoft TF. Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Mol Oncol. 2007;1:181–95.

    Article  PubMed  Google Scholar 

  18. Spijker S, Van Zanten JS, De Jong S, Penninx BW, van Dyck R, Zitman FG, Smit JH, Ylstra B, Smit AB, Hoogendijk WJ. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry. 2010;68(2):179–86. Epub 2010 May 14.

    Article  PubMed  CAS  Google Scholar 

  19. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004;5:211–24.

    Article  PubMed  CAS  Google Scholar 

  20. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000;9(1):3–28.

    PubMed  CAS  Google Scholar 

  21. Fujimura T, Takahashi S, Urano T, Kumagai J, Murata T, Takayama K, Ogushi T, Horie-Inoue K, Ouchi Y, Kitamura T, Muramatsu M, Homma Y, Inoue S. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology. 2009;74:391–7.

    Article  PubMed  Google Scholar 

  22. Siemes C, Visser LE, de Jong FH, Coebergh JW, Uitterlinden AG, Hofman A, Stricker BH, van Schaik RH. Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer–The Rotterdam Study. Steroids. 2010;75:1024–32.

    Article  PubMed  CAS  Google Scholar 

  23. Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One. 2008;3:e2079.

    Article  PubMed  Google Scholar 

  24. Luxen S, Belinsky SA, Knaus UG. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res. 2008;68:1037–45.

    Article  PubMed  CAS  Google Scholar 

  25. McDonald ER III, El-Deiry WS. Cell cycle control as a basis for cancer drug development (Review). Int J Oncol. 2000;16:871–86.

    PubMed  CAS  Google Scholar 

  26. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem. 2001;8:1487–503.

    PubMed  CAS  Google Scholar 

  27. Mukhopadhyay UK, Senderowicz AM, Ferbeyre G. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res. 2005;65:2872–81.

    Article  PubMed  CAS  Google Scholar 

  28. Kavitha CV, Choudhary B, Raghavan SC, Muniyappa K. Differential regulation of MRN (Mre11-Rad50-Nbs1) complex subunits and telomerase activity in cancer cells. Biochem Biophys Res Commun. 2010;399:575–80.

    Article  PubMed  CAS  Google Scholar 

  29. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA. 2007;104:8438–43.

    Article  PubMed  CAS  Google Scholar 

  30. Lindsey-Boltz LA, Sancar A. Tethering DNA damage checkpoint mediator proteins TopBP1 and Claspin to DNA activates ATR phosphorylation of Chk1. J Biol Chem. 2011;286:19229–36.

    Article  PubMed  CAS  Google Scholar 

  31. Gao T, Newton AC. The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. J Biol Chem. 2002;277:31585–92.

    Article  PubMed  CAS  Google Scholar 

  32. Kaufman L, Potla U, Coleman S, Dikiy S, Hata Y, Kurihara H, He JC, D’Agati VD, Klotman PE. Up-regulation of the homophilic adhesion molecule sidekick-1 in podocytes contributes to glomerulosclerosis. J Biol Chem. 2010;285:25677–85.

    Article  PubMed  CAS  Google Scholar 

  33. Chung S, Furihata M, Tamura K, Uemura M, Daigo Y, Nasu Y, Miki T, Shuin T, Fujioka T, Nakamura Y, Nakagawa H. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene. 2009;28:2849–59.

    Article  PubMed  CAS  Google Scholar 

  34. Konishi N, Shimada K, Nakamura M, Ishida E, Ota I, Tanaka N, Fujimoto K. Function of JunB in transient amplifying cell senescence and progression of human prostate cancer. Clin Cancer Res. 2008;14:4408–16.

    Article  PubMed  CAS  Google Scholar 

  35. Tomkova K, Tomka M, Zajac V. Contribution of p53, p63, and p73 to the developmental diseases and cancer. Neoplasma. 2008;55:177–81.

    PubMed  CAS  Google Scholar 

  36. Grisanzio C, Signoretti S. p63 in prostate biology and pathology. J Cell Biochem. 2008;103:1354–68.

    Article  PubMed  CAS  Google Scholar 

  37. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58:619–24.

    Article  PubMed  CAS  Google Scholar 

  38. Kiefer J, Alexander A, Farach-Carson MC. Type I collagen-mediated changes in gene expression and function of prostate cancer cells. Cancer Treat Res. 2004;118:101–24.

    Article  PubMed  CAS  Google Scholar 

  39. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21:1156–67. Epub 2008 Jun 20.

    Article  PubMed  CAS  Google Scholar 

  40. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007;38:564–9.

    Article  PubMed  CAS  Google Scholar 

  41. Wang Q, Zheng JY, Kreth J, Yan X, Kamata M, Campbell RA, Xie Y, Chiu R, Berenson JR, Shi W, Chen IS, Pang S. Regulation of prostate-specific antigen expression by the junctional adhesion molecule A. Urology. 2009;73:1119–25.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Natural Science Foundation of Guangdong Province (04003650), National Natural Science Foundation of China (30872960), Key projects of Bureau of Health in Guangzhou Municipality (201102A212015) and projects of Guangdong Key Laboratory of Urology (2010A060801016).

Conflict of interest

All authors disclose any association that poses a conflict of interest in connection with the manuscript.

Author information

Authors and Affiliations

  1. Department of Urology, Guangzhou First Municipal People’s Hospital, Affiliated Guangzhou Medical College, 510180, Guangzhou, China

    Jia-hong Chen, Hui-chan He, Fu-neng Jiang, Guo-qiang Qin, Chao Cai, Xi-bin Chen, Yan-ru Chen & Wei-de Zhong

  2. Guangdong Provincial Institute of Nephrology, Southern Medical University, 510515, Guangzhou, China

    Wei-de Zhong

  3. Guangdong Key Laboratory of Urology, 510230, Guangzhou, Guangdong, China

    Wei-de Zhong

  4. Department of Biology, University of Rochester, Rochester, NY, USA

    Julia Militar & Petor-yang Ran

  5. State Key Lab of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical College, Guangzhou Medical College, 510120, Guangzhou, China

    Jin Zhao & Zi-yao Mo

  6. Department of Urology, Guizhou Provincial People’s Hospital, 550002, Guizhou, China

    Jian-guo Zhu

  7. Department of Genetics, Albert Einstein College of Medicine, New York, NY, USA

    Xingyin Liu

Authors
  1. Jia-hong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui-chan He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fu-neng Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julia Militar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Petor-yang Ran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guo-qiang Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chao Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xi-bin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zi-yao Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yan-ru Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jian-guo Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Xingyin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Wei-de Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xingyin Liu or Wei-de Zhong.

Additional information

Jia-hong Chen and Hui-chan He contributed equally to this work.

Microarray data are available on GEO (GSE28204).

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Jh., He, Hc., Jiang, Fn. et al. Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population. Med Oncol 29, 1972–1984 (2012). https://doi.org/10.1007/s12032-011-0088-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0088-5

Keywords

Search

Navigation